New imaging technique maps immune cells in inflammatory bowel disease

Inflammatory bowel disease kills tissue from the inside out. The immune system, meant to protect the gut, instead attacks it—and for years, researchers have struggled to see exactly which immune cells are doing the damage and how they're organized within the inflamed tissue itself. A new imaging technique is beginning to change that.

Researchers developed a platform called ChipCytometry that can map immune cells directly in colon tissue samples with unprecedented detail. The method uses a panel of 20 markers—molecular tags that identify different cell types and their activation states—to create a high-resolution portrait of immune infiltration. The team applied it to tissue samples from two healthy volunteers, five patients with ulcerative colitis, and five with Crohn's disease, two distinct forms of inflammatory bowel disease that cause chronic inflammation of the digestive tract.

What emerged were distinct immune signatures for each disease. In ulcerative colitis tissue, helper T cells flooded the inflamed areas at much higher levels than in healthy tissue. These helper cells also showed elevated expression of a protein called S1P1, which regulates how immune cells move through the body and how aggressively they respond to threats. The colitis samples contained more S1P1-positive immune cells overall—a sign that the inflammatory machinery was running at high intensity. Crohn's disease tissue told a different story. There, plasma cells—the antibody-producing descendants of B cells—accumulated in abnormally high numbers. Meanwhile, natural killer cells, which normally help control inflammation, were depleted in both disease types compared to healthy controls.

The finding that helper T cells dominate the immune infiltrate in ulcerative colitis, and that they preferentially express S1P1, points toward a potential therapeutic angle. S1P1 signaling controls lymphocyte trafficking—essentially, it's the mechanism that tells immune cells where to go and when to stay put. If that pathway could be modulated, it might be possible to reduce the recruitment or activation of these cells without shutting down immunity entirely. The same logic applies to the plasma cell overabundance in Crohn's disease, though the cellular target would be different.

What makes ChipCytometry valuable is not just what it reveals about individual cell types, but where it reveals it. Traditional immune profiling often grinds up tissue and loses spatial information—you learn what cells are present, but not how they're organized or which cells are sitting next to which. This platform preserves that architecture. Researchers can see immune cells in their actual tissue context, which matters because a helper T cell next to an epithelial cell behaves differently than one clustered with other immune cells. The 20-marker panel allows simultaneous identification of multiple cell types and their functional states in a single sample, creating a multidimensional map rather than a flat list.

The study is small—five patients per disease group is a modest sample—but it demonstrates proof of concept. The technique works. It produces interpretable, biologically coherent results. The next phase will be larger cohorts, longitudinal tracking of how immune profiles change over time, and testing whether the S1P1 pathway emerges as a viable drug target. For patients with inflammatory bowel disease, who currently manage their condition with broad immunosuppressants that carry their own risks, a more precise understanding of which cells are driving inflammation in which patients could eventually mean more targeted, less toxic treatment.